Denali Therapeutics Inc.

General ticker "DNLI" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $3.6B (TTM average)

Denali Therapeutics Inc. follows the US Stock Market performance with the rate: 40.2%.

Estimated limits based on current volatility of 2.6%: low 15.71$, high 16.55$

Factors to consider:

  • Earnings expected soon, date: 2025-05-06 bmo
  • Price in estimated range
  • Earnings for 12 months up through Q4 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [12.88$, 27.16$]
  • 2024-12-30 to 2025-12-30 estimated range: [12.17$, 25.60$]

Financial Metrics affecting the DNLI estimates:

  • Negative: Non-GAAP EPS, $ of -1.08 <= 0.04
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -11.47 <= 1.79
  • Negative: negative Operating income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: negative Industry operating income (median)
  • Negative: Industry operating cash flow per share per price (median), % of -24.70 <= 2.82

Similar symbols

Short-term DNLI quotes

2025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-2911121314151617
Price $

Long-term DNLI plot with estimates

101520253035Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025−0.500.51
DNLIS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $48.66MM $108.46MM $330.53MM
Operating Expenses $344.41MM $449.21MM $527.23MM
Operating Income $-295.75MM $-340.74MM $-196.70MM
Non-Operating Income $4.59MM $14.77MM $51.51MM
R&D Expense $265.35MM $358.73MM $423.88MM
Income(Loss) $-291.16MM $-325.97MM $-145.19MM
Taxes $-0.57MM $0.02MM $0.03MM
Profit(Loss)* $-290.58MM $-325.99MM $-145.22MM
Stockholders Equity $962.29MM $1,042.43MM $1,030.95MM
Inventory $0.00MM $5.00MM $0.00MM
Assets $1,404.16MM $1,460.24MM $1,153.92MM
Operating Cash Flow $-211.39MM $-244.72MM $-357.99MM
Capital expenditure $8.50MM $17.83MM $12.94MM
Investing Cash Flow $-21.63MM $-141.39MM $249.31MM
Financing Cash Flow $19.35MM $310.67MM $17.82MM
Earnings Per Share** $-2.39 $-2.60 $-1.06

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.